Compare ARK Genomic Revolution ETF (ARKG) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Main Street Capital Corporation — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while Main Street Capital Corporation trades at $52.88 (market cap $4.91B). The key difference: Main Street Capital Corporation pays a 8.29% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Main Street Capital Corporation nearer its low. Which is the better fit depends on your goals.
| ARKG | MAIN | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $67.54 |
52-Week Low | $23.09 | $49.63 |
Market Cap | — | $4.91B |
Dividend Yield | — | 8.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Main Street Capital (MAIN) trades at $52.84, up 2.26% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong profitability with an 81.08% net margin and 14.37% ROE, though recent quarters show inconsistent earnings performance with two misses and one beat. Revenue declined slightly from $601M in 2024 to $592M in 2025, with further contraction projected for 2026. The stock pays consistent dividends, with recent payments ranging from $0.26 to $0.30 per share.
MAIN presents a cautious outlook with analysts showing 78.57% hold ratings despite a $57.75 consensus price target suggesting 9.3% upside. The bearish technical trend and projected revenue decline to $526M in 2026 create headwinds, while strong profitability metrics and dividend consistency provide support. Investors face balancing attractive valuation (P/E 11.12) against earnings volatility and negative operating cash flow of -$45.71M in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
